Cargando…

Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature

Background: Hidradenitis suppurativa (HS), also known as acne inversa or Verneuil’s disease, is a chronic, inflammatory, recurrent, and debilitating skin disease of the hair follicles characterized by inflammatory, painful, deep-rooted lesions in the areas of the body characterized by the presence o...

Descripción completa

Detalles Bibliográficos
Autores principales: Martora, Fabrizio, Scalvenzi, Massimiliano, Ruggiero, Angelo, Potestio, Luca, Battista, Teresa, Megna, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146646/
https://www.ncbi.nlm.nih.gov/pubmed/37109759
http://dx.doi.org/10.3390/medicina59040801
_version_ 1785034628379181056
author Martora, Fabrizio
Scalvenzi, Massimiliano
Ruggiero, Angelo
Potestio, Luca
Battista, Teresa
Megna, Matteo
author_facet Martora, Fabrizio
Scalvenzi, Massimiliano
Ruggiero, Angelo
Potestio, Luca
Battista, Teresa
Megna, Matteo
author_sort Martora, Fabrizio
collection PubMed
description Background: Hidradenitis suppurativa (HS), also known as acne inversa or Verneuil’s disease, is a chronic, inflammatory, recurrent, and debilitating skin disease of the hair follicles characterized by inflammatory, painful, deep-rooted lesions in the areas of the body characterized by the presence of the apocrine glands. Unfortunately, huge unmet needs still remain for its treatment. Objective: The purpose of our review was collecting all cases, case series, trials, and ongoing studies available in the literature on the use of this class of drugs for HS. Materials and Methods: The investigated manuscripts included trials, reviews, letters to the editor, real-life studies, case series, and reports. Manuscripts were identified, screened, and extracted for the relevant data following the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines. Results: We selected 56 articles of which 25 met the selection criteria for our review. Among the JAK inhibitors to date, there is only one published clinical trial in the literature (Janus kinase 1 inhibitor INCB054707), a real-life study with 15 patients up to week 24 in which upadacitinib was used and a case series where tofacitinib was successfully used. Conversely, there are several ongoing clinical trials. Conclusions: Results to date in the literature show promising levels of efficacy and the safety of JAK inhibitors in HS. Several clinical trials are underway from which it will be very important to compare the available data. There are still too few studies conducted with a low sample size, so it remains critical to investigate this issue further in the future with a real-life study involving a large sample of patients in order to provide safe and viable therapeutic alternatives for HS.
format Online
Article
Text
id pubmed-10146646
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101466462023-04-29 Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature Martora, Fabrizio Scalvenzi, Massimiliano Ruggiero, Angelo Potestio, Luca Battista, Teresa Megna, Matteo Medicina (Kaunas) Review Background: Hidradenitis suppurativa (HS), also known as acne inversa or Verneuil’s disease, is a chronic, inflammatory, recurrent, and debilitating skin disease of the hair follicles characterized by inflammatory, painful, deep-rooted lesions in the areas of the body characterized by the presence of the apocrine glands. Unfortunately, huge unmet needs still remain for its treatment. Objective: The purpose of our review was collecting all cases, case series, trials, and ongoing studies available in the literature on the use of this class of drugs for HS. Materials and Methods: The investigated manuscripts included trials, reviews, letters to the editor, real-life studies, case series, and reports. Manuscripts were identified, screened, and extracted for the relevant data following the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines. Results: We selected 56 articles of which 25 met the selection criteria for our review. Among the JAK inhibitors to date, there is only one published clinical trial in the literature (Janus kinase 1 inhibitor INCB054707), a real-life study with 15 patients up to week 24 in which upadacitinib was used and a case series where tofacitinib was successfully used. Conversely, there are several ongoing clinical trials. Conclusions: Results to date in the literature show promising levels of efficacy and the safety of JAK inhibitors in HS. Several clinical trials are underway from which it will be very important to compare the available data. There are still too few studies conducted with a low sample size, so it remains critical to investigate this issue further in the future with a real-life study involving a large sample of patients in order to provide safe and viable therapeutic alternatives for HS. MDPI 2023-04-20 /pmc/articles/PMC10146646/ /pubmed/37109759 http://dx.doi.org/10.3390/medicina59040801 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Martora, Fabrizio
Scalvenzi, Massimiliano
Ruggiero, Angelo
Potestio, Luca
Battista, Teresa
Megna, Matteo
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature
title Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature
title_full Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature
title_fullStr Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature
title_full_unstemmed Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature
title_short Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature
title_sort hidradenitis suppurativa and jak inhibitors: a review of the published literature
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146646/
https://www.ncbi.nlm.nih.gov/pubmed/37109759
http://dx.doi.org/10.3390/medicina59040801
work_keys_str_mv AT martorafabrizio hidradenitissuppurativaandjakinhibitorsareviewofthepublishedliterature
AT scalvenzimassimiliano hidradenitissuppurativaandjakinhibitorsareviewofthepublishedliterature
AT ruggieroangelo hidradenitissuppurativaandjakinhibitorsareviewofthepublishedliterature
AT potestioluca hidradenitissuppurativaandjakinhibitorsareviewofthepublishedliterature
AT battistateresa hidradenitissuppurativaandjakinhibitorsareviewofthepublishedliterature
AT megnamatteo hidradenitissuppurativaandjakinhibitorsareviewofthepublishedliterature